The global deferiprone market size accounted for USD 41.56 million in 2025 and is forecasted to hit around USD 57.14 million by 2034, representing a CAGR of 3.60% from 2025 to 2034. The North America market size was estimated at USD 16.05 million in 2024 and is expanding at a CAGR of 3.72% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Deferiprone Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Deferiprone Market Revenue and Volume, by Type
8.1.1 Capsule
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Oral Solutions
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Tablets
8.1.3.1. Market Revenue and Volume Forecast
9.1. Deferiprone Market Revenue and Volume, by Therapeutic Use
9.1.1. Iron Overload Disorders
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Sickle Cell Disease Treatment
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Thalassemia Treatment
9.1.3.1. Market Revenue and Volume Forecast
10.1. Deferiprone Market Revenue and Volume, by Indication
10.1.1. NTDT Caused Overload
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Transfusional Iron Overload
10.1.2.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Type
11.1.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.1.3. Market Revenue and Volume Forecast, by Indication
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Type
11.1.4.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.1.4.3. Market Revenue and Volume Forecast, by Indication
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Type
11.1.5.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.1.5.3. Market Revenue and Volume Forecast, by Indication
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Type
11.2.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.2.3. Market Revenue and Volume Forecast, by Indication
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Type
11.2.4.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.2.4.3. Market Revenue and Volume Forecast, by Indication
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Type
11.2.5.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.2.5.3. Market Revenue and Volume Forecast, by Indication
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Type
11.2.6.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.2.6.3. Market Revenue and Volume Forecast, by Indication
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Type
11.2.7.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.2.7.3. Market Revenue and Volume Forecast, by Indication
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Type
11.3.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.3.3. Market Revenue and Volume Forecast, by Indication
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Type
11.3.4.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.3.4.3. Market Revenue and Volume Forecast, by Indication
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Type
11.3.5.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.3.5.3. Market Revenue and Volume Forecast, by Indication
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Type
11.3.6.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.3.6.3. Market Revenue and Volume Forecast, by Indication
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Type
11.3.7.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.3.7.3. Market Revenue and Volume Forecast, by Indication
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Type
11.4.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.4.3. Market Revenue and Volume Forecast, by Indication
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Type
11.4.4.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.4.4.3. Market Revenue and Volume Forecast, by Indication
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Type
11.4.5.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.4.5.3. Market Revenue and Volume Forecast, by Indication
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Type
11.4.6.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.4.6.3. Market Revenue and Volume Forecast, by Indication
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Type
11.4.7.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.4.7.3. Market Revenue and Volume Forecast, by Indication
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Type
11.5.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.5.3. Market Revenue and Volume Forecast, by Indication
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Type
11.5.4.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.5.4.3. Market Revenue and Volume Forecast, by Indication
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Type
11.5.5.2. Market Revenue and Volume Forecast, by Therapeutic Use
11.5.5.3. Market Revenue and Volume Forecast, by Indication
12.1. Apotex Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Chiesi Farmaceutici S.p.A
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Cipla Limited
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Novartis International AG
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Sun Pharmaceutical Industries Ltd.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Taro Pharmaceutical Industries Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. VHB Life Sciences Limited
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Zydus Cadila
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample